Aussie Chemgenex Licenses Leukemia Drug To Support U.S. Push
This article was originally published in PharmAsia News
Australia's Chemgenex has signed a deal with U.S.-based Hospira that could be worth $119.4 million to the Australian firm by the time it runs its course
You may also be interested in...
WASHINGTON - Hospira announced Dec. 15 it will purchase Orchid Chemicals & Pharmaceuticals' generic injectable drug business for $400 million, thereby filling one gap in the company's broadening therapeutic coverage
The new committee, which will initially be in place for a year, will advise the French drug regulator when it is preparing its opinions on substitution in specific biosimilar product groups.
IVD manufacturers look set to be granted up to 18 more months to comply with the EU IVD Regulation very soon.